Philip E Castle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5462751/publications.pdf

Version: 2024-02-01

213 papers	13,995 citations	26567 56 h-index	22764 112 g-index
214 all docs	214 docs citations	214 times ranked	9175 citing authors

#	Article	IF	Citations
1	Adherence to National Guidelines on Cervical Screening: A Population-Based Evaluation From a Statewide Registry. Journal of the National Cancer Institute, 2022, 114, 626-630.	3.0	5
2	Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. Journal of the National Cancer Institute, 2022, 114, 845-853.	3.0	12
3	National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. BMJ, The, 2022, 376, e068582.	3.0	16
4	Automated Evaluation of p16/Ki-67 Dual-Stain Cytology as a Biomarker for Detection of Anal Precancer in Men Who Have Sex With Men and Are Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2022, 75, 1565-1572.	2.9	6
5	Metaâ€analysis of agreement/concordance statistics in studies comparing selfâ€vs clinicianâ€collected samples for <scp>HPV</scp> testing in cervical cancer screening. International Journal of Cancer, 2022, 151, 308-312.	2.3	31
6	HPV testing of self-samples: Influence of collection and sample handling procedures on clinical accuracy to detect cervical precancer. Lancet Regional Health - Europe, The, 2022, 14, 100332.	3.0	12
7	Reply to: Comments on â€œMetaâ€analysis of agreement/concordance statistics in studies comparing selfâ€vs clinicianâ€collected samples for HPV testing in cervical cancer screeningâ€. International Journal of Cancer, 2022, 151, 484-487.	2.3	0
8	Redefining precision cancer prevention to promote health equity. Trends in Cancer, 2022, 8, 295-302.	3.8	3
9	Different human papillomavirus types share early natural history transitions in immunocompetent women. International Journal of Cancer, 2022, 151, 920-929.	2.3	5
10	Accuracy and Efficiency of Deep-Learningâ€“Based Automation of Dual Stain Cytology in Cervical Cancer Screening. Journal of the National Cancer Institute, 2021, 113, 72-79.	3.0	82
11	Comparison of immediate colposcopy, repeat conventional cytology and highâ€risk human papillomavirus testing for the clinical management of atypical squamous cells of undetermined significance cytology in routine health services of Medellin, Colombia: The <scp>ASCUSâ€COL</scp> trial. International Journal of Cancer, 2021, 148, 1394-1407.	2.3	5
12	Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 72, 1529-1537.	2.9	8
13	Given a choice between self-sampling at home for HPV testing and standard of care screening at the clinic, what do African American women choose? Findings from a group randomized controlled trial. Preventive Medicine, 2021, 142, 106358.	1.6	11
14	Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating highâ€resolution microendoscopy to detect cervical precancer. International Journal of Cancer, 2021, 148, 2571-2578.	2.3	9
15	Feasibility and performance of the fecal immunochemical test (FIT) for average-risk colorectal cancer screening in Nigeria. PLoS ONE, 2021, 16, e0243587.	1.1	9
16	Challenges and opportunities associated with cervical cancer screening programs in a low income, high HIV prevalence context. BMC Women's Health, 2021, 21, 74.	0.8	16
17	Type-specific persistence, clearance and incidence of high-risk HPV among screen-positive Rwandan women living with HIV. Infectious Agents and Cancer, 2021, 16, 16.	1.2	5
18	A Pilot Study of Human Papillomavirus Detection in Urine Using a Novel Nucleic Acid Amplification Test. journal of applied laboratory medicine, The, 2021, 6, 474-479.	0.6	3

#	Article	IF	Citations
19	Reply to: Comments on Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating highâ€resolution microendoscopy to detect cervical precancer. International Journal of Cancer, 2021, 149, 969-971.	2.3	0
20	The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses. Gynecologic Oncology, 2021, 161, 297-303.	0.6	3
21	A lay health worker intervention to improve breast and cervical cancer screening among Latinas in El Paso, Texas: A randomized control trial. Preventive Medicine, 2021, 145, 106446.	1.6	8
22	Genetic and Epigenetic Variations of HPV52 in Cervical Precancer. International Journal of Molecular Sciences, 2021, 22, 6463.	1.8	9
23	Letter to the Editor: Persisting Health Disparities in Women Living with HIV from the US. Clinical Infectious Diseases, 2021, , .	2.9	0
24	Letter to the Editor Re: A population study of screening history and diagnostic outcomes of women with invasive cervical cancer. Cancer Medicine, 2021, 10, 7263-7264.	1.3	1
25	Cervical cancer prevention and control in women living with human immunodeficiency virus. Ca-A Cancer Journal for Clinicians, 2021, 71, 505-526.	157.7	70
26	Phylogenomic Analysis of Human Papillomavirus Type 31 and Cervical Carcinogenesis: A Study of 2093 Viral Genomes. Viruses, 2021, 13, 1948.	1.5	7
27	The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0865.2021.	1.1	3
28	Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. International Journal of Cancer, 2020, 146, 617-626.	2.3	5
29	Epidemiological evidence that common HPV types may be common because of their ability to evade immune surveillance: Results from the Women's Interagency HIV study. International Journal of Cancer, 2020, 146, 3320-3328.	2.3	9
30	Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. Archives of Pathology and Laboratory Medicine, 2020, 144, 725-734.	1.2	30
31	The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador. Preventive Medicine, 2020, 131, 105931.	1.6	9
32	Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. Infectious Agents and Cancer, 2020, 15, 60.	1.2	27
33	A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States. Gynecologic Oncology, 2020, 159, 344-353.	0.6	9
34	Anogenital Human Papillomavirus and HIV Infection in Rwandan Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 463-469.	0.9	9
35	A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine, 2020, 22, 100293.	3.2	109
36	A comparison of screening tests for detection of high-grade cervical abnormalities in women living with HIV from Cameroon. Infectious Agents and Cancer, 2020, 15, 45.	1.2	4

#	Article	IF	Citations
37	A scoping review: Facilitators and barriers of cervical cancer screening and early diagnosis of breast cancer in Sub-Saharan African health settings. Gynecologic Oncology Reports, 2020, 33, 100605.	0.3	35
38	A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirusâ€“positive and -Negative Cervical Precancers. Cancer Prevention Research, 2020, 13, 829-840.	0.7	6
39	Is It Time for Risk-based Screening Guidelines for the Prevention of Anal Cancer?. Clinical Infectious Diseases, 2020, 73, 30-32.	2.9	0
40	Outcomes for Step-Wise Implementation of a Human Papillomavirus Testingâ€“Based Cervical Screen-and-Treat Program in El Salvador. JCO Global Oncology, 2020, 6, 1519-1530.	0.8	12
41	The Capulana study: a prospective evaluation of cervical cancer screening using human papillomavirus testing in Mozambique. International Journal of Gynecological Cancer, 2020, 30, 1292-1297.	1.2	12
42	Utilizing Cultural and Ethnic Variables in Screening Models to Identify Individuals at High Risk for Gastric Cancer: A Pilot Study. Cancer Prevention Research, 2020, 13, 687-698.	0.7	5
43	Association of <scp>HPV35</scp> with cervical carcinogenesis among women of African ancestry: Evidence of viralâ€host interaction with implications for disease intervention. International Journal of Cancer, 2020, 147, 2677-2686.	2.3	44
44	A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15â€year cervical cancer screening experience at Kaiser Permanente Northern California. International Journal of Cancer, 2020, 147, 1612-1620.	2.3	15
45	Cervicovaginal microbiome and natural history of HPVÂin a longitudinal study. PLoS Pathogens, 2020, 16, e1008376.	2.1	150
46	2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease, 2020, 24, 102-131.	0.9	608
47	Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 132-143.	0.9	116
48	Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. Nature Communications, 2020, 11, 886.	5.8	52
49	High-risk human papillomavirus prevalence in self-collected cervicovaginal specimens from human immunodeficiency virus (HIV)-negative women and women living with HIV living in Botswana. PLoS ONE, 2020, 15, e0229086.	1.1	18
50	Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. British Journal of Cancer, 2020, 122, 1715-1723.	2.9	43
51	A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 144-147.	0.9	48
52	Cervical human papillomavirus DNA detection in women living with HIV and HIV-uninfected women living in Limbe, Cameroon. Journal of Clinical Virology, 2020, 128, 104445.	1.6	8
53	Twelve-Year Trend in the Prevalence of High-Risk Human Papillomavirus Infection Among Rwandan Women Living With HIV. Journal of Infectious Diseases, 2020, 222, 74-81.	1.9	9
54	Title is missing!. , 2020, 15, e0229086.		0

#	Article	IF	Citations
55	Title is missing!. , 2020, 15, e0229086.		0
56	Title is missing!. , 2020, 15, e0229086.		0
57	Title is missing!. , 2020, 15, e0229086.		0
58	An Exploratory Analysis of Fecal Immunochemical Test Performance for Colorectal Cancer Screening in Nigeria. World Journal of Surgery, 2019, 43, 2674-2680.	0.8	4
59	The costâ€effectiveness of implementing HPV testing for cervical cancer screening in El Salvador. International Journal of Gynecology and Obstetrics, 2019, 145, 40-46.	1.0	20
60	Social contexts as mediator of risk behaviors in Rwandan men who have sex with men (MSM): Implications for HIV and STI transmission. PLoS ONE, 2019, 14, e0211099.	1.1	23
61	(At Least) Once in Her Lifetime: Global Cervical Cancer Prevention. Obstetrics and Gynecology Clinics of North America, 2019, 46, 107-123.	0.7	12
62	The burden of cervical cancer in Vietnam: Synthesis of the evidence. Cancer Epidemiology, 2019, 59, 83-103.	0.8	13
63	Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. JAMA Internal Medicine, 2019, 179, 881.	2.6	98
64	Towards global elimination of cervical cancer in all groups of women â€“ Authors' reply. Lancet Oncology, The, 2019, 20, e239.	5.1	0
65	Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. Gynecologic Oncology, 2019, 152, 465-471.	0.6	14
66	Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020â€“99: a modelling study. Lancet Oncology, The, 2019, 20, 394-407.	5.1	279
67	Perceived Susceptibility to Cervical Cancer among African American Women in the Mississippi Delta: Does Adherence to Screening Matter?. Women's Health Issues, 2019, 29, 38-47.	0.9	12
68	5-Year Prospective Evaluation of Cytology, Human Papillomavirus Testing, and Biomarkers for Detection of Anal Precancer in Human Immunodeficiency Virusâ€Positive Men Who Have Sex With Men. Clinical Infectious Diseases, 2019, 69, 631-638.	2.9	29
69	Participation in Cervical Screening by Self-collection, Pap, or a Choice of Either in Brazil. Cancer Prevention Research, 2019, 12, 159-170.	0.7	20
70	Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. JAMA Oncology, 2019, 5, 181.	3.4	79
71	Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. Preventive Medicine, 2019, 118, 44-50.	1.6	21
72	FightHPV: Design and Evaluation of a Mobile Game to Raise Awareness About Human Papillomavirus and Nudge People to Take Action Against Cervical Cancer. JMIR Serious Games, 2019, 7, e8540.	1.7	34

#	Article	IF	Citations
73	Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. Journal of Clinical Microbiology, 2018, 56, .	1.8	18
74	Charting the Future of Cancer Health Disparities Researchâ€"Letter. Cancer Research, 2018, 78, 1883-1885.	0.4	3
75	Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology. Journal of the National Cancer Institute, 2018, 110, 1222-1228.	3.0	12
76	Can a gastric cancer risk survey identify high-risk patients for endoscopic screening? A pilot study. Journal of Surgical Research, 2018, 227, 246-256.	0.8	9
77	Timely followâ€up of positive cancer screening results: A systematic review and recommendations from the <scp>PROSPR</scp> Consortium. Ca-A Cancer Journal for Clinicians, 2018, 68, 199-216.	157.7	63
78	Diagnosing Cervical Neoplasia in Rural Brazil Using a Mobile Van Equipped with In Vivo Microscopy: A Cluster-Randomized Community Trial. Cancer Prevention Research, 2018, 11, 359-370.	0.7	25
79	Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21â€"39 Years. Cancer Prevention Research, 2018, 11, 165-170.	0.7	26
80	Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. Journal of the National Cancer Institute, 2018, 110, 501-508.	3.0	116
81	Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25â€"69 years living in Australia. BMJ Open, 2018, 8, e016700.	0.8	20
82	Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women. Clinical Cancer Research, 2018, 24, 2194-2202.	3.2	75
83	Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting. Preventive Medicine, 2018, 109, 44-50.	1.6	14
84	A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix. Gynecologic Oncology, 2018, 148, 422-429.	0.6	81
85	Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. Journal of Clinical Virology, 2018, 99-100, 22-30.	1.6	32
86	Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records. Preventive Medicine, 2018, 111, 429-435.	1.6	15
87	Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy. Journal of Lower Genital Tract Disease, 2018, 22, 97-103.	0.9	5
88	Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.. Preventive Medicine, 2018, 111, 177-179.	1.6	7
89	Anal Cancer Risk Among People With HIV Infection in the United States. Journal of Clinical Oncology, 2018, 36, 68-75.	0.8	152
90	Reply to M. Swanson et al. Journal of Global Oncology, 2018, 4, 1-2.	0.5	0

#	Article	IF	Citations
91	Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer. Journal of Clinical Oncology, 2018, 36, 1184-1191.	0.8	65
92	Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ: British Medical Journal, 2018, 363, k4823.	2.4	437
93	Protocol for the study of cervical cancer screening technologies in HIV-infected women living in Rwanda. BMJ Open, 2018, 8, e020432.	0.8	12
94	A pilot case control study: Could a gastric cancer risk screening tool help identify high risk patients for endoscopic screening in the United States?. Journal of Clinical Oncology, 2018, 36, 64-64.	0.8	0
95	When Less is More. Journal of the National Cancer Institute, 2017, 109, djw240.	3.0	1
96	Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?. Journal of Clinical Microbiology, 2017, 55, 2348-2355.	1.8	10
97	Cervical cancer prevention in El Salvador (CAPE)â€"An HPV testing-based demonstration project: Changing the secondary prevention paradigm in a lower middle-income country. Gynecologic Oncology Reports, 2017, 20, 58-61.	0.3	17
98	Smoking and subsequent human papillomavirus infection: a mediation analysis. Annals of Epidemiology, 2017, 27, 724-730.e1.	0.9	33
99	Correspondence regarding Suba et al., human papillomavirus screening for low and middle-income countries. Preventive Medicine, 2017, 105, 356.	1.6	0
100	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell, 2017, 170, 1164-1174.e6.	13.5	221
101	The Cost-Effectiveness of Visual Triage of Human Papillomavirusâ€"Positive Women in Three Low- and Middle-Income Countries. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1500-1510.	1.1	13
102	Treatment of cervical intraepithelial lesions. International Journal of Gynecology and Obstetrics, 2017, 138, 20-25.	1.0	53
103	Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records. Statistics in Medicine, 2017, 36, 3583-3595.	0.8	25
104	Why does cervical cancer occur in a state-of-the-art screening program?. Gynecologic Oncology, 2017, 146, 546-553.	0.6	47
105	Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. Journal of Global Oncology, 2017, 3, 635-657.	0.5	121
106	Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico. Journal of Rural Health, 2017, 33, 382-392.	1.6	25
107	Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era. JAMA Oncology, 2017, 3, 833.	3.4	88
108	Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Medicine, 2017, 14, e1002388.	3.9	67

#	Article	IF	Citations
109	Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. Journal of Oncology Practice, 2017, 13, 129-133.	2.5	22
110	Screening to Prevent Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. Journal of Clinical Oncology, 2017, 35, 1250-1252.	0.8	14
111	Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer. Clinical Infectious Diseases, 2017, 65, 893-899.	2.9	58
112	Age of human papillomavirus vaccination?. Lancet Infectious Diseases, The, 2016, 16, 1091-1093.	4.6	4
113	Response. Journal of the National Cancer Institute, 2016, 108, djv390.	3.0	0
114	HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women. Journal of the National Cancer Institute, 2016, 108, djw100.	3.0	147
115	Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1595-1599.	1.1	12
116	Will cervical screening remain costâ€effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. International Journal of Cancer, 2016, 139, 2771-2780.	2.3	62
117	A paper-based immunoassay to determine HPV vaccination status at the point-of-care. Vaccine, 2016, 34, 5656-5663.	1.7	10
118	A cohort study of cervical screening using partial HPV typing and cytology triage. International Journal of Cancer, 2016, 139, 2606-2615.	2.3	68
119	Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study. BMC Infectious Diseases, 2016, 16, 698.	1.3	10
120	Association of High-Risk Human Papillomavirus with Genital Tract Mucosal Immune Factors in HIV-Infected Women. American Journal of Reproductive Immunology, 2016, 75, 146-154.	1.2	7
121	A risk-based framework to decide who benefits from screening. Nature Reviews Clinical Oncology, 2016, 13, 531-532.	12.5	11
122	Risk assessment to guide cervical screening strategies in a large <scp>C</scp>hinese population. International Journal of Cancer, 2016, 138, 2639-2647.	2.3	16
123	Time for a Model List of Essential Diagnostics. New England Journal of Medicine, 2016, 374, 2511-2514.	13.9	36
124	A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Gynecologic Oncology, 2016, 141, 364-370.	0.6	21
125	Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 36-42.	1.1	14
126	Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathology, 2015, 123, 566-566.	1.4	6

#	Article	IF	Citations
127	When Is It Effective to Offer Self-Sampling to Non-Attendeesâ€"Letter. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1295-1295.	1.1	3
128	The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology. Journal of Clinical Virology, 2015, 69, 52-55.	1.6	10
129	PSA testing for prostate cancer screening. Lancet Oncology, The, 2015, 16, e2-e3.	5.1	11
130	Comparison of Human Papillomavirus Detection by Aptima HPV and cobas HPV Tests in a Population of Women Referred for Colposcopy following Detection of Atypical Squamous Cells of Undetermined Significance by Pap Cytology. Journal of Clinical Microbiology, 2015, 53, 1277-1281.	1.8	39
131	Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 769-772.	1.1	100
132	Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test. Clinical Infectious Diseases, 2015, 61, 1573-1581.	2.9	34
133	A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecologic Oncology, 2015, 138, 573-578.	0.6	49
134	The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1304-1310.	1.1	44
135	A joint model of persistent human papilloma virus infection and cervical cancer risk: implications for cervical cancer screening. Journal of the Royal Statistical Society Series A: Statistics in Society, 2015, 178, 903-923.	0.6	6
136	p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. Journal of the National Cancer Institute, 2015, 107, djv257.	3.0	130
137	A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing. Journal of Clinical Virology, 2015, 69, 210-213.	1.6	16
138	Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test. Journal of the National Cancer Institute, 2014, 106, dju153-dju153.	3.0	200
139	Response. Journal of the National Cancer Institute, 2014, 107, dju390-dju390.	3.0	0
140	Three-Year Risk of Cervical Precancer and Cancer After the Detection of Low-Risk Human Papillomavirus Genotypes Targeted by a Commercial Test. Obstetrics and Gynecology, 2014, 123, 49-56.	1.2	9
141	A new method to address verification bias in studies of clinical screening tests: cervical cancer screening assays as an example. Journal of Clinical Epidemiology, 2014, 67, 343-353.	2.4	14
142	Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda. Infectious Agents and Cancer, 2014, 9, 40.	1.2	17
143	Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1313-1318.	1.1	38
144	A Comparison of Human Papillomavirus Genotype-Specific DNA and E6/E7 mRNA Detection to Identify Anal Precancer among HIV-Infected Men Who Have Sex with Men. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 42-49.	1.1	23

#	Article	IF	Citations
145	Risk of Cervical Precancer and Cancer Among HIV-Infected Women With Normal Cervical Cytology and No Evidence of Oncogenic HPV Infection. JAMA - Journal of the American Medical Association, 2012, 308, 362-9.	3.8	63
146	Safety Against Cervical Precancer and Cancer Following Negative Human Papillomavirus and Papanicolaou Test Results in Human Immunodeficiency Virusâ€“Infected Women. Archives of Internal Medicine, 2012, 172, 1041-3.	4.3	6
147	Long-Term Persistence of Prevalently Detected Human Papillomavirus Infections in the Absence of Detectable Cervical Precancer and Cancer. Journal of Infectious Diseases, 2011, 203, 814-822.	1.9	47
148	Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncology, The, 2011, 12, 663-672.	5.1	504
149	Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncology, The, 2011, 12, 880-890.	5.1	440
150	The Clinical Meaning of a Cervical Intraepithelial Neoplasia Grade 1 Biopsy. Obstetrics and Gynecology, 2011, 118, 1222-1229.	1.2	35
151	Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Preventive Medicine, 2011, 52, 452-455.	1.6	82
152	Human Papillomavirus (HPV) Genotypes in Women with Cervical Precancer and Cancer at Kaiser Permanente Northern California. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 946-953.	1.1	66
153	Variable Risk of Cervical Precancer and Cancer After a Human Papillomavirusâ€“Positive Test. Obstetrics and Gynecology, 2011, 117, 650-656.	1.2	13
154	Relationship of Atypical Glandular Cell Cytology, Age, and Human Papillomavirus Detection to Cervical and Endometrial Cancer Risks. Obstetrics and Gynecology, 2010, 115, 243-248.	1.2	73
155	The Age-Specific Relationships of Abnormal Cytology and Human Papillomavirus DNA Results to the Risk of Cervical Precancer and Cancer. Obstetrics and Gynecology, 2010, 116, 76-84.	1.2	71
156	Impact of Improved Classification on the Association of Human Papillomavirus With Cervical Precancer. American Journal of Epidemiology, 2010, 171, 155-163.	1.6	26
157	Human Papillomavirus Genotypes in Cervical Intraepithelial Neoplasia Grade 3. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1675-1681.	1.1	43
158	Commentary on Statement on HPV DNA Test Utilization. American Journal of Clinical Pathology, 2009, 131, 770-773.	0.4	2
159	Evaluation of a Prototype Real-Time PCR Assay for Carcinogenic Human Papillomavirus (HPV) Detection and Simultaneous HPV Genotype 16 (HPV16) and HPV18 Genotyping. Journal of Clinical Microbiology, 2009, 47, 3344-3347.	1.8	50
160	Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ: British Medical Journal, 2009, 339, b2569-b2569.	2.4	167
161	Influence of Loop Electrosurgical Excision Procedure on Subsequent Acquisition of New Human Papillomavirus Infections. Journal of Infectious Diseases, 2009, 199, 1612-1620.	1.9	8
162	Age-appropriate use of human papillomavirus vaccines in the U.S.. Gynecologic Oncology, 2009, 114, 365-369.	0.6	28

#	Article	IF	Citations
163	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. International Journal of Cancer, 2009, 124, 516-520.	2.3	557
164	Neither oneâ€time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. International Journal of Cancer, 2009, 125, 1649-1656.	2.3	15
165	How to evaluate emerging technologies in cervical cancer screening?. International Journal of Cancer, 2009, 125, 2489-2496.	2.3	91
166	The evolving definition of carcinogenic human papillomavirus. Infectious Agents and Cancer, 2009, 4, 7.	1.2	33
167	Cervical Cancers After Human Papillomavirus Vaccination. Obstetrics and Gynecology, 2009, 114, 174.	1.2	1
168	Evidence for Frequent Regression of Cervical Intraepithelial Neoplasiaâ€“Grade 2. Obstetrics and Gynecology, 2009, 113, 18-25.	1.2	321
169	Effect of the Number of Biopsies on the Subsequent Acquisition of New Human Papillomavirus Infections. Obstetrics and Gynecology, 2009, 114, 1057-1062.	1.2	6
170	Five-Year Experience of Human Papillomavirus DNA and Papanicolaou Test Cotesting. Obstetrics and Gynecology, 2009, 113, 595-600.	1.2	97
171	Impact of 6-month frozen storage of cervical specimens in alkaline buffer conditions on human papillomavirus genotyping. Journal of Virological Methods, 2008, 151, 298-300.	1.0	6
172	Comparison of Linear Array and Line Blot Assay for Detection of Human Papillomavirus and Diagnosis of Cervical Precancer and Cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study. Journal of Clinical Microbiology, 2008, 46, 109-117.	1.8	91
173	Human Papillomavirus Genotype Specificity of Hybrid Capture 2. Journal of Clinical Microbiology, 2008, 46, 2595-2604.	1.8	156
174	Comparison of Two PCR-Based Human Papillomavirus Genotyping Methods. Journal of Clinical Microbiology, 2008, 46, 3437-3445.	1.8	75
175	Invited Commentary: Is Monitoring of Human Papillomavirus Infection for Viral Persistence Ready for Use in Cervical Cancer Screening?. American Journal of Epidemiology, 2008, 168, 138-144.	1.6	28
176	The Potential Utility of HPV Genotyping in Screening and Clinical Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 83-95.	2.3	13
177	Factors Influencing Histologic Confirmation of High-Grade Squamous Intraepithelial Lesion Cytology. Obstetrics and Gynecology, 2008, 112, 637-645.	1.2	17
178	An Analysis of High-Risk Human Papillomavirus DNA-Negative Cervical Precancers in the ASCUS-LSIL Triage Study (ALTS). Obstetrics and Gynecology, 2008, 111, 847-856.	1.2	44
179	Risk Assessment to Guide the Prevention of Cervical Cancer. Journal of Lower Genital Tract Disease, 2008, 12, 1-7.	0.9	59
180	A Cross-sectional Study of a Prototype Carcinogenic Human Papillomavirus E6/E7 Messenger RNA Assay for Detection of Cervical Precancer and Cancer. Clinical Cancer Research, 2007, 13, 2599-2605.	3.2	95

#	Article	IF	Citations
181	Mouthwash as a Low-Cost and Safe Specimen Transport Medium for Human Papillomavirus DNA Testing of Cervicovaginal Specimens. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 840-843.	1.1	13
182	The Relationship of Community Biopsy-Diagnosed Cervical Intraepithelial Neoplasia Grade 2 to the Quality Control Pathology-Reviewed Diagnoses. American Journal of Clinical Pathology, 2007, 127, 805-815.	0.4	186
183	A Comparison of Cervical and Vaginal Human Papillomavirus. Sexually Transmitted Diseases, 2007, 34, 849-855.	0.8	73
184	Human papillomavirus and cervical cancer. Lancet, The, 2007, 370, 890-907.	6.3	2,343
185	Risk assessment to guide the prevention of cervical cancer. American Journal of Obstetrics and Gynecology, 2007, 197, 356.e1-356.e6.	0.7	140
186	Human Papillomavirus Prevalence in Women Who Have and Have Not Undergone Hysterectomies. Journal of Infectious Diseases, 2006, 194, 1702-1705.	1.9	24
187	Pilot Study of a Commercialized Human Papillomavirus (HPV) Genotyping Assay: Comparison of HPV Risk Group to Cytology and Histology. Journal of Clinical Microbiology, 2006, 44, 3915-3917.	1.8	35
188	Detection of Carcinogenic Human Papillomavirus in Specimens Collected with a Novel Self-Sampling Device. Journal of Clinical Microbiology, 2006, 44, 2158-2159.	1.8	11
189	Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. International Journal of Cancer, 2005, 117, 1007-1012.	2.3	40
190	Epidemiologic Profile of Typeâ€Specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica. Journal of Infectious Diseases, 2005, 191, 1796-1807.	1.9	322
191	Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities. Journal of the National Cancer Institute, 2005, 97, 1066-1071.	3.0	273
192	A Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence in Guanacaste, Costa Rica. Journal of Infectious Diseases, 2005, 191, 1808-1816.	1.9	354
193	Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. Cancer Letters, 2005, 229, 245-252.	3.2	49
194	PCR testing of pooled longitudinally collected cervical specimens of women to increase the efficiency of studying human papillomavirus infection. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 256-60.	1.1	2
195	A novel filtration-based processing method of liquid cytology specimens for human papillomavirus DNA testing by hybrid capture II. American Journal of Clinical Pathology, 2005, 123, 250-5.	0.4	0
196	A Populationâ€Based Study of Vaginal Human Papillomavirus Infection in Hysterectomized Women. Journal of Infectious Diseases, 2004, 190, 458-467.	1.9	72
197	Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. American Journal of Obstetrics and Gynecology, 2004, 191, 1590-1597.	0.7	31
198	Comparison of Ophthalmic Sponges for Measurements of Immune Markers from Cervical Secretions. Vaccine Journal, 2004, 11, 399-405.	3.2	33

#	Article	IF	Citations
199	Beyond Human Papillomavirus: The Cervix, Exogenous Secondary Factors, and the Development of Cervical Precancer and Cancer. Journal of Lower Genital Tract Disease, 2004, 8, 224-230.	0.9	32
200	Interlaboratory reliability of Hybrid Capture 2. American Journal of Clinical Pathology, 2004, 122, 238-45.	0.4	59
201	Effects of Electron-Beam Irradiation on Buccal-Cell DNA. American Journal of Human Genetics, 2003, 73, 646-651.	2.6	12
202	Comparison between Prototype Hybrid Capture 3 and Hybrid Capture 2 Human Papillomavirus DNA Assays for Detection of High-Grade Cervical Intraepithelial Neoplasia and Cancer. Journal of Clinical Microbiology, 2003, 41, 4022-4030.	1.8	55
203	Chlamydia trachomatis, Herpes Simplex Virus 2, and Human T-Cell Lymphotrophic Virus Type 1 Are Not Associated With Grade of Cervical Neoplasia in Jamaican Colposcopy Patients. Sexually Transmitted Diseases, 2003, 30, 575-580.	0.8	34
204	Chapter 4: Genital Tract Infections, Cervical Inflammation, and Antioxidant Nutrients--Assessing Their Roles as Human Papillomavirus Cofactors. Journal of the National Cancer Institute Monographs, 2003, 2003, 29-34.	0.9	144
205	Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 1449-56.	1.1	10
206	A Prospective Study of High-Grade Cervical Neoplasia Risk Among Human Papillomavirus-Infected Women. Journal of the National Cancer Institute, 2002, 94, 1406-1414.	3.0	208
207	Results of Human Papillomavirus DNA Testing with the Hybrid Capture 2 Assay Are Reproducible. Journal of Clinical Microbiology, 2002, 40, 1088-1090.	1.8	70
208	Sexual Behavior, Human Papillomavirus Type 16 (HPV 16) Infection, and HPV 16 Seropositivity. Sexually Transmitted Diseases, 2002, 29, 182-187.	0.8	34
209	Comparisons of HPV DNA detection by MY09/11 PCR methods. Journal of Medical Virology, 2002, 68, 417-423.	2.5	158
210	Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer, 2002, 95, 2145-2151.	2.0	84
211	Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. Journal of Clinical Immunology, 2002, 22, 23-27.	2.0	42
212	Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1394-9.	1.1	57
213	Cervical HPV DNA Detection as a Predictor of a Recurrent SIL Diagnosis Among Untreated Women. Journal of Lower Genital Tract Disease, 2001, 5, 138-143.	0.9	1